Bausch & Lomb
This article was originally published in The Gray Sheet
Completes acquisition of hearing aid manufacturer Dahlberg with the approval of Dahlberg shareholders July 30. B&L acquired Dahlberg for about $139 mil. ($21 per share) under the terms of an agreement that had been modified to account for costs associated with addressing charges against Dahlberg by the Federal Trade Commission ("The Gray Sheet" May 24, I&W-9). Under the original letter of intent between the firms, B&L would have paid $158 million ($24 per share). B&L is consolidating the operations of its former hearing systems division into Golden Valley, Minnesota-based Dahlberg, which will operate as a subsidiary.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.